Minocycline is a recent addition to the long list of drugs that may cause lupus or at least a lupus-like syndrome. The inclusion of minocycline is important given its frequent and often prolonged use for the treatment of acne in young people. An estimated 800 000 prescriptions for minocycline were written in 1993 in the United Kingdom. 1 From national PACT (prescribing analysis and cost) data, use of minocycline peaked in 1994 and 1995 at about 5.5 million de®ned daily doses per quarter year. 2 Use declined sharply to 70% of previous levels in early 1996 following publication of a paper reporting cases of minocycline-induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome, 1 and to 62% in subsequent quarters. However, the use of minocycline remains frequent and awareness of adverse effects together with adequate monitoring systems would seem prudent.
Adverse effects from minocycline such as hyperpigmentation 3 and pseudotumour cerebri 4 have been known for some time. Systemic autoimmune disorders such as pneumonitis 5 and autoimmune hepatitis 1,6 are well recorded. Following the initial report of minocycline-induced lupus 7 there have been numerous further case reports and series. 1, 8, 9 Common features have been the development of an in¯ammatory arthritis, skin rashes, andaor an autoimmune hepatitis. Ourselves and others have reported a high frequency of p-ANCA in cases, 10, 11 although anti-double-stranded DNA antibodies and anticardiolipin antibodies may also occur. However, unlike idiopathic SLE there appears to be an absence of antibodies to RNA binding proteins. Clinical and serological features abate following drug withdrawal, usually quite rapidly but not uncommonly over several months. The risk of development of idiopathic SLE following minocycline use is not known but is likely to be minimal unless there is further exposure to an identical inciting agent.
A recent nested case-control study of 27 688 acne patients aged 15 ±29 y using computer records of general practitioners has shed some light on the incidence of minocycline-induced lupus. 12 The study reported an 8.5-fold risk of developing a lupus-like syndrome with current use of minocycline compared to non-users and past users of tetracyclines combined. The risk increased to 16-fold with current exposure to minocycline and a cumulative dose above 100 de®ned daily doses. The crude incidence rate for lupus-like syndrome associated with current use of any tetracycline was 14.2 cases per 100 000 prescriptions. The rate of lupus-like syndrome in females was 17.2 cases per 100 000 prescriptions for oxytetracycline and 52.8 cases per 100 000 prescriptions for minocycline. Therefore, there appear to be properties unique to minocycline in comparison to other tetracyclines that are associated with its ability to induce lupus.
Studies of thyroid disease have supported the notion that at least some of the toxic effects of minocycline may be mediated by oxidised metabolites. Minocycline may act as a substrate for thyroid peroxidase leading to the release of reactive intermediates. 13 In preliminary work we have demonstrated that minocycline-induced toxicity is myeloperoxidase dependent. 10 It has been suggested that a common feature of lupus-inducing drugs may be their ability to act as an alternate substrate for chloride ions and become oxidised by myeloperoxidase to toxic intermediates. 14 The site of release of putative toxic metabolites such as in the liver and in circulating in¯ammatory cells may explain the pattern of injury and systemic involvement in minocycline-induced lupus syndrome. It is intriguing that myeloperoxidase itself becomes a target for an autoimmune response in such individuals. Similarly, the enzymes involved in metabolising minocycline in the liver may be targeted, possibly by binding of the reactive intermediates that act as haptens and induce an autoimmune response to an altered neoantigen. A 50 kDa protein of rat liver microsomes recognised by serum from a case of minocycline-induced autoimmune hepatitis has been reported. 15 In addition to its antibacterial action, minocycline has immunomodulatory properties and inhibits the activity of matrix metalloproteinases. It is not known which of these properties may explain its modest bene®t for patients with rheumatoid arthritis. For instance, minocycline seems to down-regulate the release of tumor necrosis factor alpha (TNF-a) from T cells but enhances TNF-a and IL-6 release from lipopolysaccaride-stimulated monocytes. 16 Therefore, minocycline may have different effects on TNF-a production depending on the type of cell involved. Conceivably, the release of TNF-a from monocytes may contribute to pathways leading to enhanced apoptosis and autoreactivity. There is increasing evidence that apoptotic cells comprise a major source of immunogenic material on their cell surface. In this regard it is worth noting that anti-MPO antibodies are capable of interacting directly with primary granules that have been translocated to the cell surface following priming with TNF-a 17 or following apoptosis. 18 Thus, it is possible to envisage a model of ongoing toxic injury to in¯ammatory cells mediated via reactive intermediates of minocycline that, together with release of cytokines such as TNF-a, induce accelerated apoptosis and an accompanying cycle of autoreactivity.
Host susceptibility factors are likely to be important as not everyone, and indeed relatively few, individuals develop lupus with minocycline. MHC Class II genes are obvious candidates especially in light of the accompanying autoantibody response. Relatively small studies only seem possible at present. Elkayam et al found four of six patients positive for HLA DRB1 1104*. 11 Our own results suggest an association with either HLA-DR4 or HLA-DR2 (manuscript submitted). Other candidate genes, such as those encoding cytokines including TNF-a and IL-1, apoptosis genes and drug-metabolising genes would be worth studying if suf®ciently large numbers of patients could be recruited.
The long half-life of minocycline and the relative lack of induction of bacterial resistance explain its ongoing appeal for the treatment of acne. That appeal needs to be tempered by awareness of possible adverse effects. In addition, the instigation of regular checks in individuals taking minocycline for prolonged periods with liver function tests and an autoimmune screen including an ANCA seems warranted.
